Y Intercept (Hong Kong) LTD Fate Therapeutics Inc Transaction History

Y Intercept (Hong Kong) LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $55,592 - $120,735	17,053 New	17,053 $55,000
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $127,494 - $318,104	63,116 Added 193.71%	95,698 $202,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $155,090 - $214,715	32,582 New	32,582 $155,000
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $305,027 - $410,231	-6,376 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $73,968 - $119,471	1,248 Added 24.34%	6,376 $378,000
Q2 2021 Aug 26, 2021	BUY	$67.25 - $92.52 $344,858 - $474,442	5,128 New	5,128 $445,000
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $0 - $0	0 New	0 $445,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $182M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.